Citadel Advisors’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Citadel Advisors’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-16,000	Closed	-$6K	–	10174
2018 Q2	$6K	Buy	+16,000	New	+$13.1K	﹤0.01%	8733
2017 Q4	–	Sell	-11,700	Closed	-$27K	–	8874
2017 Q3	$27K	Buy	11,700 +400	+4%	+$535	﹤0.01%	7314
2017 Q2	$15K	Buy	+11,300	New	+$16.3K	﹤0.01%	7345
2017 Q1	–	Sell	-10,700	Closed	-$47K	–	8581
2016 Q4	$47K	Sell	10,700 -1,500	-12%	-$7.12K	﹤0.01%	6887
2016 Q3	$59K	Buy	+12,200	New	+$55.6K	﹤0.01%	6820
2016 Q2	–	Sell	-18,800	Closed	-$67K	–	8004
2016 Q1	$67K	Buy	+18,800	New	+$96.9K	﹤0.01%	6177

Other funds holding ARLZ

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Citadel Advisors's ARLZ Position: Q3 2018 in Review

Citadel Advisors sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 16,471 shares — an estimated $6K sold.

Citadel Advisors first reported a position in ARLZ in Q1 2016 and held it in 7 quarters. The position peaked at $221K in Q4 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

Citadel Advisors reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
Citadel Advisors sold 16,471 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $6K.
Citadel Advisors first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 7 quarters.
Citadel Advisors's Aralez Pharmaceuticals Inc. position peaked at $221K in Q4 2016.
4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Citadel Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.